Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DMX 101 - Dimerix Bioscience

Next Previous
X
Search
Drug Profile

DMX 101 - Dimerix Bioscience

Alternative Names: DMX-101 - Dimerix Bioscience

Latest Information Update: 06 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dimerix Bioscience
  • Class Anti-inflammatories; Immunoglobulin Fc fragments; Immunoglobulin fusion proteins; Irritable bowel syndrome therapies; Opioid analgesics; Recombinant fusion proteins; Tumour necrosis factors
  • Mechanism of Action Opioid kappa receptor antagonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Irritable bowel syndrome
  • Phase I Pain

Most Recent Events

  • 21 Sep 2023 Phase-I clinical trials in Pain (PO), before September 2023
  • 21 Sep 2023 Phase-II/III clinical trials in Irritable bowel syndrome (PO), before September 2023
  • 21 Sep 2023 DMX 101 receives Fast track status from the US FDA for Irritable bowel syndrome, prior to September 2023 (Dimerix Bioscience pipeline, September 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top